Vitreoretinal Lymphoma: From Pathobiology to Integrated Diagnosis
- 1Department of Sense Organs, Sapienza University of Rome, 00161 Rome, Italy
- 2Helvetia Retina Associates, MIOS SA, 1005 Lausanne, Switzerland
- 3New York Eye and Ear Infirmary of Mt Sinai, Icahn School of Medicine, New York, NY 10003, USA
Abstract
Vitreoretinal lymphoma (VRL) is a rare, high-grade intraocular malignancy able to mimic intermediate and/or posterior uveitis. Diagnosis is difficult because lymphomatous cells in ocular samples are scarce, fragile and rapidly degraded, particularly after corticosteroid exposure. This review examines how current knowledge of VRL pathobiology is reflected in its clinical, imaging and laboratory features and how these can inform diagnosis. Cytology remains the confirmatory test, while multimodal imaging helps localise vitreous, intraretinal and sub retinal pigmented epithelium (RPE) involvement and guides ocular sampling. Diagnostic yield depends on appropriate sample collection, handling and timely processing. Cytokine and molecular testing, including interleukin-10 (IL-10)/interleukin-6 (IL-6) assessment and detection of recurrent lymphoma-associated alterations such as MYD88 and CD79B, can provide diagnostic support when morphology is inconclusive. We also examine newer approaches designed to increase the information obtained from small-volume ocular samples through quantitative imaging and high-dimensional molecular profiling. The diagnostic value of each test depends on the anatomical distribution of disease and the characteristics of the specimen and is greatest when complementary findings are interpreted together.
Related
- Clinical Features of Vitreoretinal Lymphoma Recurrences
- Effectiveness and safety of treatments for new-onset, refractory and relapsed vitreoretinal lymphoma: protocol for a systematic review and network meta-analysis.
- Diagnostic Yield of Vitreous Biopsy and MYD88 Mutation Analysis in Vitreoretinal Lymphoma: A Retrospective Cohort Study.
- Routine Clinical Nemolizumab Use Before or After Cutaneous T-Cell Lymphoma Diagnosis
- Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma∗
BibTeX
@article{saturno2026vitreoretinal,
title = {{Vitreoretinal Lymphoma: From Pathobiology to Integrated Diagnosis}},
author = {Maria Carmela Saturno and Danilo Iannetta and Alessandro Lambiase and Marc D. de Smet},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18203262},
url = {https://www.mdpi.com/2072-6694/18/20/3262},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Vitreoretinal Lymphoma: From Pathobiology to Integrated Diagnosis
AU - Maria Carmela Saturno
AU - Danilo Iannetta
AU - Alessandro Lambiase
AU - Marc D. de Smet
PY - 2026
DA - 2026/10/01
JO - Cancers
DO - 10.3390/cancers18203262
UR - https://www.mdpi.com/2072-6694/18/20/3262
AB - Vitreoretinal lymphoma (VRL) is a rare, high-grade intraocular malignancy able to mimic intermediate and/or posterior uveitis. Diagnosis is difficult because lymphomatous cells in ocular samples are scarce, fragile and rapidly degraded, particularly after corticosteroid exposure. This review examines how current knowledge of VRL pathobiology is reflected in its clinical, imaging and laboratory features and how these can inform diagnosis. Cytology remains the confirmatory test, while multimodal imaging helps localise vitreous, intraretinal and sub retinal pigmented epithelium (RPE) involvement and guides ocular sampling. Diagnostic yield depends on appropriate sample collection, handling and timely processing. Cytokine and molecular testing, including interleukin-10 (IL-10)/interleukin-6 (IL-6) assessment and detection of recurrent lymphoma-associated alterations such as MYD88 and CD79B, can provide diagnostic support when morphology is inconclusive. We also examine newer approaches designed to increase the information obtained from small-volume ocular samples through quantitative imaging and high-dimensional molecular profiling. The diagnostic value of each test depends on the anatomical distribution of disease and the characteristics of the specimen and is greatest when complementary findings are interpreted together.
SN - 2072-6694
ER -